Glioblastoma has a poor prognosis, with few therapeutic options if it recurs. We report a case in which we were able to inhibit the growth of a recurrent glioblastoma by weekly single-dose administration of interferon-beta.
Case report
A patient with recurrent glioblastoma after radiation and chemotherapy was treated with nimustine and interferon-beta. After 2 cycles of nimustine, the patient's leukocyte, neutrophil, and platelet counts showed grade 4 toxicity according to the National Cancer Institute's Common Toxicity Criteria. The patient was treated with a weekly single dose of interferon-beta at 6 × 106 IU. The tumor showed no remarkable changes after 18 months, and the patient's Karnofsky performance status remained at 50%.
Conclusions
The administration of interferon-beta produced long-term control in one case of glioblastoma and may be an effective therapy. Free full text available at www.tumorionline.it
YungW.K., AlbrightR.E., OlsonJ., FredericksR., FinkK., PradosM.D., BradaM., SpenceA., HohlR.J., ShapiroW., GlantzM., GreenbergH., SelkerR.G., VickN.A., RamplingR., FriedmanH., PhillipsP., BrunerJ., YueN., OsobaD., ZaknoenS., LevinV.A.: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.Br J Cancer, 83: 588–593, 2000.
2.
YungW.K., PradosM.D., Yaya-TurR., RosenfeldS.S., BradaM., FriedmanH.S., AlbrightR., OlsonJ., ChangS.M., O'NeillA.M., FriedmanA.H., BrunerJ., YueN., DuganM., ZaknoenS., LevinV.A.: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.J Clin Oncol, 17: 2762–2771, 1999.
3.
StuppR., MasonW.P., van den BentM.J., WellerM., FisherB., TaphoornM.J., BelangerK., BrandesA.A., MarosiC., BogdahnU., CurschmannJ., JanzerR.C., LudwinS.K., GorliaT., AllgeierA., LacombeD., CairncrossJ.G., EisenhauerE., MirimanoffR.O.: For the European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N Engl J Med, 352: 987–996, 2005.
4.
AngioliR., SevinB.U., PerrasJ.P., UntchM., KoechliO.R., NguyenH.N., SterenA., SchwadeJ.G., VillaniC., AveretteH.E.: In vitro potentiation of radiation cytotoxicity by recombinant interferons in cervical cancer cell lines.Cancer, 71: 3717–3725, 1993.
5.
ColmanH., BerkeyB.A., MaorM.H., GrovesM.D., SchultzC.J., VermeulenS., NelsonD.F., MehtaM.P., YungW.K.: Radiation Therapy Oncology Group: Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710.Int J Radiat Oncol Biol Phys, 66: 818–824, 2006.
6.
KuboH., AshidaA., MatsumotoK., KageshitaT., YamamotoA., SaidaT.: Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells.Arch Dermatol Res, 300: 297–301, 2008.
7.
SaitoR., MizunoM., HatanoM., KumabeT., YoshimotoT., YoshidaJ.: Two different mechanisms of apoptosis resistance observed in interferon-beta induced apoptosis of human glioma cells.J Neurooncol, 67: 273–280, 2004.
8.
YoshinoA., KatayamaY., YokoyamaT., WatanabeT., OginoA., OtaT., KomineC., FukushimaT., KusamaK.: Therapeutic implications of interferon regulatory factor (IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to interferon (IFN)-beta in glioblastoma cells and prognostic value for DIA.J Neurooncol, 74: 249–260, 2005.
9.
GarrisonJ.I., BerensM.E., ShapiroJ.R., TreasurywalaS., Floyd-SmithG.: Interferon-beta inhibits proliferation and progression through S phase of the cell cycle in five glioma cell lines.J Neurooncol, 30: 213–223, 1996.
10.
VitaleG., de HerderW.W., van KoetsveldP.M., WaaijersM., SchoordijkW., CrozeE., ColaoA., LambertsS.W., HoflandL.J.: IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro.Cancer Res, 66: 554–562, 2006.
11.
KitoT., KurodaE., YokotaA., YamashitaU.: Enhancement of macrophage cytotoxicity against murine gliomas by interferon beta: increase in nitric oxide production in response to glioma-derived soluble factors.J Neurosurg, 97: 619–626, 2002.
StreckC.J., NgC.Y., ZhangY., ZhouJ., NathwaniA.C., DavidoffA.M.: Interferon-mediated anti-angiogenic therapy for neuroblastoma.Cancer Lett, 228: 163–170, 2005.
14.
TaylorK.L., LeamanD.W., GraneR., MechtiN., BordenE.C., LindnerD.J.: Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro.J Interferon Cytokine Res, 28: 733–740, 2008.
15.
YaoY., KubotaT., SatoK., TakeuchiH., HandaY., MatsukawaS.: Cell-specific but p53-independent regulation of vascular endothelial growth factor expression by interferons in human glioblastoma cells.J Neurooncol, 76: 219–225, 2006.
16.
FujimakiT., IshiiH., MatsunoA., AraiH., NakagomiT.: Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma.World J Surg Oncol, 5: 89, 2007.
17.
NatsumeA., IshiiD., WakabayashiT., TsunoT., HatanoH., MizunoM., YoshidaJ.: IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.Cancer Res, 65: 7573–7579, 2005.
18.
ParkJ.A., JoeY.A., KimT.G., HongY.K.: Potentiation of antiglioma effect with combined temozolomide and interferon-beta.Oncol Rep, 16: 1253–1260, 2006.
19.
HatanoN., WakabayashiT., KajitaY., MizunoM., OhnoT., NakayashikiN., TakemuraA., YoshidaJ.: Efficacy of post operative adjuvant therapy with human interferon beta, MC-NU and radiation (IMR) for malignant glioma: comparison among three protocols.Acta Neurochir (Wien), 142: 633–639, 2000.
20.
WatanabeT., KatayamaY., YoshinoA., FukayaC., YamamotoT.: Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas.J Neurooncol, 72: 57–62, 2005.
21.
AokiT., TakahashiJ.A., UebaT., OyaN., HiraokaM., MatsuiK., FukuiT., NakashimaY., IshikawaM., HashimotoN.: Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group.J Neurosurg, 105: 385–391, 2006.
22.
HeimbergerA.B., SunW., HussainS.F., DeyM., CrutcherL., AldapeK., GilbertM., HassenbuschS.J., SawayaR., SchmittlingB., ArcherG.E., MitchellD.A., BignerD.D., SampsonJ.H.: Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: a case study.Neuro Oncol, 10: 98–103, 2008.
23.
MatsunoA., FujimakiT., MizutaniA., IdeF., TanakaH., AsanoS., MiyawakiS., UnoT., TanakaJ., NakaguchiH., SasakiM., MurakamiM., YamazakiK., IshidaY.: Disappearance of gadolinium enhancement in a chemoresistant astrocytoma of the tectum after high-dose interferon beta.Tumori, 94: 853–855, 2008.
24.
WakabayashiT., KayamaT., NishikawaR., TakahashiH., YoshimineT., HashimotoM., AokiT., KurisuK., NatsumeA., OguraM., YoshidaJ.: A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA study).Jpn J Clin Oncol, 38: 715–718, 2008.
25.
WakabayashiT., NatsumeA., HashimuzeY., FujiiM., MizunoM., YoshidaJ.: A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy.J Gene Med, 10: 329–339, 2008.
